A live PRV-vectored bivalent vaccine elicits dual protection against pseudorabies virus and swine acute diarrhea syndrome coronavirus

Swine acute diarrhea syndrome coronavirus (SADS-CoV), an emerging bat-derived coronavirus, causes severe diarrhea and mortality in young hosts and exhibits cross-species transmission potential. However, no licensed vaccines are currently available. In this study, we constructed a recombinant pseudorabies virus (PRV) vaccine strain, designated rPRV-SADS-S, which expresses the full-length spike (S) protein of SADS-CoV. This strain was developed based on the PRV Bartha-K61 backbone. In murine models, rPRV-SADS-S induced robust humoral and cellular immune responses against both PRV and SADS-CoV. Immunized mice exhibited complete clinical protection against lethal challenge with PRV. Notably, maternally transferred antibodies provided protection to neonatal mice against lethal SADS-CoV challenge. Moreover, in porcine models, rPRV-SADS-S provided complete clinical protection against lethal PRV challenge in piglets. Immunization of sows with rPRV-SADS-S conferred specific antibodies and neutralizing antibodies against SADS-CoV in newborn piglets and enabled them to resist SADS-CoV challenge. These results demonstrate that rPRV-SADS-S functions as a dual-target vaccine candidate, effectively mitigating the threats posed by both PRV and SADS-CoV. IMPORTANCE: Throughout history, pandemics have vividly demonstrated the reality of animal coronaviruses spilling over into human populations. This situation urgently necessitates the formulation of proactive countermeasures. Although 9 years have passed since SADS-CoV emerged in swine, there are still no licensed vaccines against this bat-derived coronavirus. To address this critical gap, we utilized the PRV Bartha-K61 vector platform to develop a novel bivalent vaccine. This strategic approach not only provides concurrent protection against PRV, a significant porcine pathogen, but also induces protective immunity against SADS-CoV. Our strategy potentially mitigates zoonotic spillover risks to humans, thereby offering a vital tool for One Health preparedness.

Authors

Institutions

Publication Details

Journal
Journal of Virology
Published
2026-10-05
DOI
https://doi.org/10.1128/jvi.01193-26
Primary Topic
Animal Virus Infections Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A live PRV-vectored bivalent vaccine elicits dual protection against pseudorabies virus and swine acute diarrhea syndrome coronavirus

Yu Zhang, Yueyue Duan, Wenquan Mao, Qi Wang et al.
Journal of Virology
Animal Virus Infections Studies
article

A live PRV-vectored bivalent vaccine elicits dual protection against pseudorabies virus and swine acute diarrhea syndrome coronavirus

Yu Zhang, Yueyue Duan, Wenquan Mao, Qi Wang, Haixue Zheng, Maowen Sun, Liyan Cao, Xiangyu Kong, Cong Yuan, Luyao Li, Juan Zhang, Xueliang Zhu, Lei Shi
article en

Abstract

Swine acute diarrhea syndrome coronavirus (SADS-CoV), an emerging bat-derived coronavirus, causes severe diarrhea and mortality in young hosts and exhibits cross-species transmission potential. However, no licensed vaccines are currently available. In this study, we constructed a recombinant pseudorabies virus (PRV) vaccine strain, designated rPRV-SADS-S, which expresses the full-length spike (S) protein of SADS-CoV. This strain was developed based on the PRV Bartha-K61 backbone. In murine models, rPRV-SADS-S induced robust humoral and cellular immune responses against both PRV and SADS-CoV. Immunized mice exhibited complete clinical protection against lethal challenge with PRV. Notably, maternally transferred antibodies provided protection to neonatal mice against lethal SADS-CoV challenge. Moreover, in porcine models, rPRV-SADS-S provided complete clinical protection against lethal PRV challenge in piglets. Immunization of sows with rPRV-SADS-S conferred specific antibodies and neutralizing antibodies against SADS-CoV in newborn piglets and enabled them to resist SADS-CoV challenge. These results demonstrate that rPRV-SADS-S functions as a dual-target vaccine candidate, effectively mitigating the threats posed by both PRV and SADS-CoV. IMPORTANCE: Throughout history, pandemics have vividly demonstrated the reality of animal coronaviruses spilling over into human populations. This situation urgently necessitates the formulation of proactive countermeasures. Although 9 years have passed since SADS-CoV emerged in swine, there are still no licensed vaccines against this bat-derived coronavirus. To address this critical gap, we utilized the PRV Bartha-K61 vector platform to develop a novel bivalent vaccine. This strategic approach not only provides concurrent protection against PRV, a significant porcine pathogen, but also induces protective immunity against SADS-CoV. Our strategy potentially mitigates zoonotic spillover risks to humans, thereby offering a vital tool for One Health preparedness.

Journal of Virology
Lanzhou Veterinary Research Institute (CN), Chinese Academy of Agricultural Sciences (CN)
Openalex Percentile: Top 14%
Animal Virus Infections Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.